Observational studyBMC neurology2026
Copeptin as a predictor of seizure diagnosis and seizure type in emergency department patients.
Observational study in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate the diagnostic utility of serum copeptin (CPT) levels in distinguishing epileptic seizures from Pseudo or functional/dissociative seizures (FDS) in adult patients presenting to the emergency department, and to investigate possible differences in CPT levels among various seizure types.
methodsThis prospective, observational study was conducted at a tertiary research hospital between September 2023 and September 2024. Adult patients presenting to the emergency department with seizure complaints were screened and, after applying exclusion criteria, 59 patients were included. Patients were classified based on clinical, laboratory, and EEG findings into epileptic seizure or FDS groups. Serum CPT and interleukin-6 (IL-6) levels were measured using ELISA.
resultsOf the 59 patients, 24 were diagnosed with epileptic seizures and 35 with FDS. No statistially significant difference was found in serum CPT levels between the epileptic seizure and FDS groups (p = 0.755). Glucose, base deficit, CRP (C-reactive protein), and IL-6 levels were significantly elevated in the epileptic seizure group relative to FDS. Serum CPT values were not predictive of clinical outcomes or the need for intensive care admission.
conclusionSerum CPT levels are not useful for differentiating between epileptic seizures and FDS in adult emergency patients. Further multicenter studies with larger cohorts and standardized sampling times are warranted to clarify the diagnostic and prognostic value of CPT in seizure disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.